<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01061281</url>
  </required_header>
  <id_info>
    <org_study_id>Tecnis MF/Crystalens</org_study_id>
    <nct_id>NCT01061281</nct_id>
  </id_info>
  <brief_title>Evaluation of the Tecnis™ Multifocal and Crystalens™ Accommodating Intraocular Lenses</brief_title>
  <official_title>Evaluation of the Tecnis™ Multifocal and Crystalens™ Accommodating Intraocular Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovative Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovative Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the visual outcomes with bilateral implantation of&#xD;
      Tecnis MF and Crystalens™ AO Aberration-free Accommodating intraocular lens (IOLs) 6 months&#xD;
      after post cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Refraction</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distance Visual Acuities</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Aphakia</condition>
  <arm_group>
    <arm_group_label>Tecnis MF IOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Crystalens AO IOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tecnis MF IOL</intervention_name>
    <description>20 patients enrolled with the Tecnis MF IOL.</description>
    <arm_group_label>Tecnis MF IOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Crystalens AO IOL</intervention_name>
    <description>20 patients enrolled with the Crystalens AO</description>
    <arm_group_label>Crystalens AO IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or greater&#xD;
&#xD;
          -  Bilateral cataracts for which phacoemulsification extraction and posterior IOL&#xD;
             implantation has been planned for both eyes&#xD;
&#xD;
          -  Visual potential of 20/25 or better in each eye after cataract removal and IOL&#xD;
             implantation&#xD;
&#xD;
          -  Preoperative best-corrected distance visual acuity (BCDVA) worse than 20/40 Snellen&#xD;
&#xD;
          -  Naturally dilated pupil size (in dim light) &gt; 4.0 mm (with no dilation medications)&#xD;
             for both eyes&#xD;
&#xD;
          -  Preoperative corneal astigmatism of 1.0 D or less&#xD;
&#xD;
          -  Clear intraocular media other than cataract&#xD;
&#xD;
          -  Availability, willingness, and sufficient cognitive awareness to comply with&#xD;
             examination procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of systemic or ocular medications that may affect vision&#xD;
&#xD;
          -  Acute or chronic disease or illness that would increase risk or confound study results&#xD;
             (e.g. diabetes mellitus, immunocompromised, etc.)&#xD;
&#xD;
          -  Subjects with diabetes mellitus&#xD;
&#xD;
          -  Uncontrolled systemic or ocular disease&#xD;
&#xD;
          -  History of ocular trauma or prior ocular surgery&#xD;
&#xD;
          -  Amblyopia or strabismus&#xD;
&#xD;
          -  Known pathology that may affect visual acuity; particularly retinal changes that&#xD;
             affect vision (macular degeneration, cystoid macular edema, proliferative diabetic&#xD;
             retinopathy, etc.)&#xD;
&#xD;
          -  Diagnosed degenerative visual disorders (e.g. macular degeneration, or other retinal&#xD;
             disorders) that are predicted to cause future acuity losses to a level of 20/30 or&#xD;
             worse&#xD;
&#xD;
          -  Subjects who may be expected to require retinal laser treatment or other surgical&#xD;
             intervention&#xD;
&#xD;
          -  Capsule or zonular abnormalities that may affect postoperative centration or tilt of&#xD;
             the lens (e.g. pseudoexfoliation syndrome)&#xD;
&#xD;
          -  Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils&#xD;
             that do not dilate at least 4.0 mm under mesopic/scotopic conditions)&#xD;
&#xD;
          -  Contact lens usage within 6 months for PMMA contacts lenses, 1 month for gas permeable&#xD;
             lenses or 1 week for extended-wear and daily-wear soft contact lenses&#xD;
&#xD;
          -  Requiring an intraocular lens &lt; 15.0 or &gt; 26.0 diopters&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Farrell Tyson</name>
      <address>
        <city>Cape Coral</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>February 1, 2010</study_first_submitted>
  <study_first_submitted_qc>February 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2010</study_first_posted>
  <last_update_submitted>January 13, 2012</last_update_submitted>
  <last_update_submitted_qc>January 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2012</last_update_posted>
  <responsible_party>
    <name_title>Farrell Tyson</name_title>
    <organization>Cape Coral Eye Center</organization>
  </responsible_party>
  <keyword>Aphakia following refractive lensectomy to treat presbyopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aphakia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

